Abstract:Background C-C chemokine receptor 1 (CCR1) and its ligands are overexpressed in synovial tissue and fluid suggesting a role in rheumatoid arthritis (RA). Early clinical studies hinted that CCR1 inhibition may be clinically efficacious. A highly selective CCR1 antagonist (BMS-817399) with high functional potency (IC50 ∼30 nM) against multiple CCR1 ligands and a favorable Phase I clinical safety profile was investigated in a proof-of-concept study in patients with RA. Objectives To test BMS-817399 clinical efficacy in RA patients based on DAS28-CRP change from baseline, and proportion of ACR 20, 50 and 70 responses at 12 weeks. Safety, pharmacokinetics and pharmacodynamics were also evaluated. Methods A Phase 2, double blind, placebo controlled clinical trial was conducted in 123 patients with moderate to severe RA (≥6 SCJ and ≥6 TJC in 28 joint count) with inadequate response to MTX (≥10 mg/week, stable for ≥6 weeks) and elevated CRP (>3mg/L). Patients were randomized 1:1:1 to placebo, 200 mg BID, or 400 mg BID on stable background MTX. The most swollen hand/wrist was imaged at baseline and Week 12 using 1.5T magnetic resonance imaging (MRI) with contrast enhancement. Results Demographic characteristics and disease activity were similar across treatment groups at baseline. The adjusted mean change (SE) from baseline in DAS28-CRP at 12 weeks was -1.20 (0.18), -1.04 (0.19) and -1.03 (0.19) in the placebo, 200 mg BID and 400 mg BID groups, respectively (adjusted for baseline disease activity and prior use of biologic DMARDs). Similarly, the proportion of ACR 20, 50 and 70 responders at 12 weeks was similar across the treatment groups, independent of prior use of biologic DMARDs. No differences were seen in any of the MRI RAMRIS components at Week 12. BMS 817399 mean trough concentrations (Cmin) at Day 15 reached steady-state and the ratios of Cmin to the ex vivo functional IC90 for MIP-1α were ∼17 and 46 for the 200 and 400 mg BID groups, respectively. Increased concentrations of ligands (MIP-1α and MIP-1β) in the serum of only BMS-817339-treated groups confirmed target engagement. Overall, BMS-817399 was safe and well-tolerated and most adverse events (AEs) were mild. No serious infections were reported in the study. Conclusions Overall, BMS-817399 was safe and well-tolerated but showed no evidence of clinical efficacy in RA patients with moderate to severe disease activity with inadequate response to MTX. No MRI improvements on synovitis or osteitis were induced by BMS-817399. Furthermore, the in vivo biologically effective CCR1 inhibition was confirmed by the selective increase of ligands only in the 2 treated arms and BMS-817399 exposures in both treated groups were at least 17x above IC90 for MIP-1α, minimizing a lack of efficacy caused by insufficient exposure or transitory target engagement. This study strongly indicates that in vivo biologically effective CCR1 inhibition does not provide clinical benefits in moderate to severe RA patients. Disclosure of Interest : A. Kivitz Grant/research support: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, P. Maciag Shareholder of: Bristol-Myers Squibb, P. Gulati Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Du Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, P. Davies Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, X. Li Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, T. Repsher Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, H. Haggerty Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, M. Londei Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb DOI 10.1136/annrheumdis-2014-eular.3871

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties.

New Dihydropyridine Derivative Attenuates NF-κB Activation Via Suppression of Calcium Influx in a Mouse BV-2 Microglial Cell Line

Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an <i>o</i>-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders

Molecular docking and dynamics guided approach to identify potential anti-inflammatory molecules as NRF2 activator to protect against drug-induced liver injury (DILI): a computational study

Identification and application of anti-inflammatory compounds screening system based on RAW264.7 cells stably expressing NF-κB-dependent SEAP reporter gene

Development of a novel class of CBP/EP300 bromodomain inhibitors which block TNF-α induced NFκB signaling

Pharmacological Evaluation of 9,10-Dihydrochromeno[8,7- E ][1,3]Oxazin-2(8 H )-One Derivatives As Potent Anti-Inflammatory Agent

Discovery of an Effective Anti-Inflammatory Agent for Inhibiting the Activation of NF-κB

Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors

Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation

Anti-Neuroinflammatory Effects of a Novel Bile Acid Derivative

A competent synthesis and efficient anti-inflammatory responses of isatinimino acridinedione moiety via suppression of in vivo NF-κB, COX-2 and iNOS signaling

Anti-Inflammatory Effects of a Novel Nuclear Factor-{kappa}B Inhibitory Derivative Derived from PyrazoloPyrimidine in Three Inflammation Models

THU0109 Lack of Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study

Design and Synthesis of Novel Cathepsin C Inhibitors with Anti-Inflammatory Activity

Site-selective synthesis and pharmacological elucidation of novel semi-synthetic analogues of koenimbine as a potential anti-inflammatory agent

Anti-inflammatory potential of selective small compounds by targeting TNF-α & NF-kB signaling: a comprehensive molecular docking and simulation study

The discovery of a novel IκB kinase β inhibitor based on pharmacophore modeling, virtual screening and biological evaluation

Unraveling Interleukin-1β inhibition: Computational insights into anti-inflammatory compound selection for inflammatory disorders

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease